Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis

Kind B, Pham C, Heinrich L, Honstein T, Heratizadeh A, Harder I, Stölzl D, Staubach-Renz P, Schaefer T, Abraham S, Augustin M, Ramaker-Brunke J, Pinter A, Meinhardt K, Quist S, Anders S, Schwarz B, Schulz-Kiesow M, Steinke S, Adler N, Handrick C, Schaekel K, Sticherling M, Bong A, Jacobs FD, Großmann B, Stahl M, Buerkle CP, Gorriahn-Maiterth HL, Biedermann T, Schmitt J, Weidinger S, Werfel T (2026)

Publication Type: Journal article

Publication year: 2026

Journal

Acta Dermato-Venereologica Society for Publication of Acta Dermato-Venereologica

Book Volume: 106

DOI: 10.2340/actadv.v106.adv-2026-0542

Abstract

Atopic dermatitis (AD) is driven by type 2 inflammation, with interleukin-13 (IL-13) as one of the central operators. Lebrikizumab is a monoclonal antibody that inhibits IL-13 signalling. Adult patients with moderate-to-severe AD who received lebrikizumab in the TREATgermany registry until 12/2024 were selected, and patient characteristics as well as effectiveness and safety outcomes after 1, 3 and 6 months were evaluated. A total of 108 patients were initiated on lebrikizumab, with 80 having follow-up data available for this analysis ("registry cohort"). Forty-one patients were switched to lebrikizumab without a "washout period" from another advanced systemic therapy ("switchers"). The mean Eczema Area and Severity Index (EASI) decreased from 14.8 at baseline to 5.6 and 3.0 at month 3 and month 6 and was comparable between switchers and nonswitchers. Clinically meaningful improvements were also seen across all patient reported outcomes (PROs) equally in both groups, e.g. a decrease of the mean peak pruritus numeric rating scale (PP-NRS) from 6.6 to 3.8 and 3.4 and the Dermatology Life Quality Index (DLQI) from 11.9 to 4.9 and 4.8. Overall, adverse events (AEs) were reported for 26.6% of patients within the first 3. The most frequently reported AE was conjunctivitis or other ocular complications, reported in 13 patients (20.3%). 32 patients (40%) had an initial EASI≥16 and were comparable to patients in lebrikizumab phase 3 studies. In this "trial-like" cohort, EASI-75 and EASI-90 response rates were 60% and 26.7% at month 3 and 70% and 50% at month 6. Lebrikizumab shows effectiveness in routine care well comparable to observations made in randomized controlled trials.

Authors with CRIS profile

Michael Sticherling Department of Dermatology

Involved external institutions

Universitätsklinikum Carl Gustav Carus Dresden DE Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz DE Germany (DE) DERMAKULM- Hautarztpraxis Dr. Jacobs & Kollegen DE Germany (DE) Technische Universität München (TUM) DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE) Hautarztpraxis Dr. Bong DE Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) DE Germany (DE) Helix Mainz GmbH & Co. KG DE Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE)

How to cite

APA:

Kind, B., Pham, C., Heinrich, L., Honstein, T., Heratizadeh, A., Harder, I.,... Werfel, T. (2026). Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis. Acta Dermato-Venereologica, 106. https://doi.org/10.2340/actadv.v106.adv-2026-0542

MLA:

Kind, Barbara, et al. "Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis." Acta Dermato-Venereologica 106 (2026).

BibTeX: Download